Thermo Fisher Scientific PRDM16 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1.0 µg/mL

View 18 publications 18 publications

Immunohistochemistry (IHC)

2 µg/mL

View 2 publications 2 publications

Immunocytochemistry (ICC/IF)

20 µg/mL

-

Product Specifications

Species Reactivity

Human, Mouse

Published species

Human, Mouse, Sheep

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

A 17 amino acid peptide from near the carboxy terminus of human PRDM16. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:PRDM16,uniProtId:Q9HAZ2-1,ncbiNodeId:9606,antigenRange:1276,antigenLength:1276,antigenImageFileName:PA5-20872_PRDM16_Q9HAZ2-1_Rabbit.svg,antigenImageFileNamePDP:PA5-20872_PRDM16_Q9HAZ2-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS

Contains

0.02% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_11154178

Product Specific Information

PA5-20872 can be used with blocking peptide PEP-0986.

Target Information

PRDM16 is a zinc finger transcription factor and contains an N-terminal PR domain. The reciprocal translocation t(1;3)(p36;q21) occurs in a subset of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This gene is located near the 1p36.3 breakpoint and has been shown to be specifically expressed in the t(1:3)(p36, q21)-positive MDS/AML. The translocation results in the overexpression of a truncated version of this protein that lacks the PR domain, which may play an important role in the pathogenesis of MDS and AML. Recent studies have shown that PRDM16 normally acts as a Smad3 binding protein that may be important for the development of orofacial structures through modulation of the TGF-beta signaling pathway. Other experiments have indicated that PRDM16 controls a bidirectional cell fate switch between skeletal myoblasts and brown fat cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.